Provided by Tiger Trade Technology Pte. Ltd.

Trinity Biotech PLC

7.05
+0.02000.28%
Volume:9K
Turnover:66.60K
Market Cap:5.73M
PE:-0.12
High:7.50
Open:7.00
Low:7.00
Close:7.03
52wk High:52.50
52wk Low:6.85
Shares:813.10K
Float Shares:669.10K
Volume Ratio:0.90
T/O Rate:1.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-60.3628
EPS(LYR):-60.3628
ROE:-1913.45%
ROA:-5.72%
PB:-0.08
PE(LYR):-0.12

Loading ...

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

MT Newswires Live
·
Apr 09

Trinity Biotech director Ronan O’Caoimh files initial beneficial ownership statement

Reuters
·
Apr 09

European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading

MT Newswires Live
·
Apr 07

Trinity Biotech interim CFO Paul Murphy files initial beneficial ownership statement

Reuters
·
Apr 03

Trinity Biotech director Andrew Omidvar files initial beneficial ownership statement

Reuters
·
Apr 03

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

MT Newswires Live
·
Apr 02

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires Live
·
Mar 31

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

MT Newswires Live
·
Mar 26

Trinity Biotech reports 85% AUC in 750-sample study of enhanced EpiCapture prostate cancer test; commercialization plans advance via New York reference laboratory

Reuters
·
Mar 25

BUZZ-Trinity Biotech rises as prostate cancer test shows strong accuracy

Reuters
·
Mar 23

Trinity Biotech Plc - Plans to Commercialize Epicapture Test Through New York Reference Laboratory

THOMSON REUTERS
·
Mar 23

Trinity Biotech Plc - New Epicapture Test Delivers Clinical Accuracy (Auc) of 85% in Latest Study

THOMSON REUTERS
·
Mar 23

Trinity Biotech Announces Successful Clinical Results for Its Enhanced Epicapture™ Prostate Cancer Test

THOMSON REUTERS
·
Mar 23